MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

Post-LOE

memantine and donepezil hydrochlorides

ANI Pharmaceuticals

ANDAORALCAPSULE, EXTENDED RELEASE

Approved

Dec 2023

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE (memantine and donepezil hydrochlorides) by ANI Pharmaceuticals is extended-release capsules contain two approved medications: memantine hydrochloride and donepezil hydrochloride. Approved for moderate to severe dementia of the alzheimer's type in patients stabilized on 10 mg of donepezil hydrochloride once daily. First approved in 2023.

Drug data last refreshed 1w ago

Mechanism of Action

extended-release capsules contain two approved medications: memantine hydrochloride and donepezil hydrochloride. Each of those medications is postulated to have a different mechanism in Alzheimer's disease. Memantine Persistent activation of central nervous system NMDA receptors by the excitatory…

Indications (1)

moderate to severe dementia of the Alzheimer's type in patients stabilized on 10 mg of donepezil hydrochloride once daily

Worked on MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.